Fig. 5
From: Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody
EgB4 nanobody does not prevent EGFR conformational rearrangement while 7D12 and 9G8/EgA1 nanobodies stabilize the inactive conformation. (Left) In the closed conformation, four nanobodies can bind to EGFR: EgB4, 7D12, 9G8 and EgA1 (PDB: 3qwq, 4krm, 4krp) [38, 41]. Here, EgB4 is modelled by superposition based on the EgB4-EGFR interface from the crystal structure reported here. (Center) In the extended monomeric conformation, only EgB4 may be able to bind to the unliganded EGFR (model based on HER2; PDB: 1n8z) [42]. (Right) Two EgB4 molecules can bind to the active dimeric EGFR. (Bottom) Corresponding schematic representations